New Yor, New York (PRWEB) August 31, 2014
The federal judge overseeing thousands of Actos bladder cancer lawsuits (http://www.theactoslawsuitcenter.com/) in the U.S. District Court, Western District of Louisiana has refused to overturn a $9 billion verdict rendered in the proceeding’s first bellwether trial, Bernstein Liebhard LLP reports. According to court documents dated August 28th, U.S. District Judge Rebecca Doherty found that the jury deciding the case properly considered evidence that suggested executives at Takeda Pharmaceuticals and Eli Lilly knew that Actos was associated with an increased risk of developing bladder cancer, and failed to adequately warn doctors and patients about this possibility. (Case No. 12-cv-00064)
“Our Firm is currently evaluating Actos lawsuits on behalf of individuals who allegedly developed bladder cancer due to long-term use of the Type 2 diabetes drug. We have been monitoring this bellwether case closely, as its outcome may indicate how juries will rule in similar claims,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to individuals who were treated with Actos for a year or more, and who allegedly went on to develop bladder cancer due to their use of the drug.
Actos Bladder Cancer Litigation
According to court documents, the case at issue in Judge Doherty’s Order was the first of more than 3,000 Actos lawsuits pending in the Western District of Louisiana to go to trial. In April, the jury hearing the case awarded the plaintiffs more than $1 million in compensatory damages and $9 billion in punitive damages. All of the claims pending in Louisiana allege that Takeda and other defendants concealed the risk of bladder cancer associated with extended use of the drug. (In re: Actos Product Liability Litigation, MDL No. 2299)
Court records show that the Actos bladder cancer litigation has been growing since June 2011, when new information was added to the drug’s label regarding its potential to cause bladder cancer. The U.S. Food & Drug Administration mandated the label change after interim results from a 10 year study suggested that taking Actos for more than 1 year was associated with a doubling of the risk of bladder cancer.
Victims of bladder cancer that was allegedly caused by Actos may be entitled to compensation from the manufacturers of the drug. To find out more about filing an Actos lawsuit, please visit Bernstein Liebhard LLP’s website. For additional information or a free legal review, please call 800-511-5092 today.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP